TANDEARIL Drug Patent Profile
✉ Email this page to a colleague
When do Tandearil patents expire, and what generic alternatives are available?
Tandearil is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in TANDEARIL is oxyphenbutazone. There is one drug master file entry for this compound. Additional details are available on the oxyphenbutazone profile page.
Summary for TANDEARIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Patent Applications: | 4,086 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TANDEARIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TANDEARIL
US Patents and Regulatory Information for TANDEARIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | TANDEARIL | oxyphenbutazone | TABLET;ORAL | 012542-004 | Sep 3, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |